前列腺癌10个显著差异表达基因筛查研究

Ten significantly differentially expressed genes in prostate cancer:Screening and verification

目的：筛查验证前列腺癌特异性表达基因。方法：运用基因芯片筛查出前列腺癌组织和癌旁组织中差异表达的基因,再通过PCR验证。结果：从芯片结果中发现,总共有1 444个基因（差异倍数≥1.5;P≤0.05）为差异表达基因。其中,前列腺癌与对比配对的良性组织有769个上调（53%）和675个下调（47%）。差异基因中有40%的差异倍数为1.5～2倍,包括396个上调和182个下调基因。另外308个上调基因和334个下调基因的差异倍数为2～5倍;46个上调基因和78个下调基因的差异倍数为5～10倍;19个上调基因和81个下调基因的差异倍数为10倍以上。取其中上调和下调最明显的各15个基因做进一步荧光定量PCR（qRT-PCR）鉴定,结果显示了大多数基因都有芯片结果相似的基因片段,芯片结果和qRT-PCR结果用皮尔森相关性分析结果为0.83,并获得10个差异显著的基因。结论：芯片分析出来的前列腺癌和良性组织间差异基因是可靠的,qRT-PCR验证获得的这10个差异基因可能成为新的肿瘤标记物和特征性肿瘤鉴定分子。

Objective：To screen and verify differentially expressed genes in prostate cancer.Methods：Using DNA microarray,we screened differentially expressed genes in prostate cancer tissue and its adjacent tissue followed by verification by PCR.Results：A total of 1 444 genes were found to be differentially expressed（ differentiation ≥1.5-fold; P≤0.05） in the prostate cancer tissue,of which 769（ 53%） were up-regulated and 675（ 47%） down-regulated.Fifty percent of the differentially expressed genes showed a 1.5- to 2-fold differentiation,including 396 up-regulated and 182 down-regulated ones.Additionally,308 up-regulated and334 down-regulated genes exhibited a 〉2- to 5-fold,46 up-regulated and 78 down-regulated genes a 〉5- to 10-fold,and 19 up-regulated and 81 down-regulated genes a 〉10-fold differentiation.Verification by subjecting 15 most significantly up-regulated and another15 most markedly down-regulated genes to quantitative real-time PCR（ qRT-PCR） showed that most of the genes had a transcriptional profile similar to that in the microarray data,with a Pearson correction coefficient of 0.83 between the microarray data and qRT-PCR results.Totally,10 significantly differentially expressed genes were identified.Conclusion：DNA microarray analysis provides reliable information on differentially expressed genes in prostate cancer and benign tissues.The 10 significantly differentially expressed genes verified by qRT-PCR could possibly become new bio-markers and specific molecules for tumor identification.